Takeda's Provigil sales force takes a hit

Share this article:
At least 500 Takeda Pharmaceutical employees who market Provigil in the US will be impacted by the announcement from Cephalon that it will end its co-promotion agreement with Takeda, Bloomberg reported. 

The partnership on the sleep-disorder agent Provigil is slated to end November 1. Takeda would not confirm the contents of the Bloomberg report, however, a Security and Exchange Commission (SEC) filing reports that 500 Takeda employees could be targeted, according to a Takeda spokesperson.  

Frazer, PA-based Cephalon cited a failure to reach a targeted goal of $850 million in sales this year as the reason for ending the agreement with Takeda. Both companies agreed that the co-promotion agreement could be severed if sales were lower than $850 million in the second year.

Cephalon is expected to add 270 sales representatives in 2009. According to industry sources, sales of Provigil rose 9.6% in the second quarter of this year to $234.8 million.

Share this article:

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.